{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:19:41Z","timestamp":1762917581734,"version":"build-2065373602"},"reference-count":13,"publisher":"Wiley","issue":"6B","license":[{"start":{"date-parts":[[2015,5,23]],"date-time":"2015-05-23T00:00:00Z","timestamp":1432339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Fitz's Cancer Warriors, David and Cynthia Chapin, the Prostate Cancer Foundation"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe outcomes of patients with prostate cancer diagnosed after another malignancy and identify factors associated with prostate cancer death in this population, as little is known about the clinical significance of prostate cancer as a subsequent malignancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      We studied 18\u00a0225 men diagnosed with prostate cancer after another malignancy from 1973 to 2006. We compared demographic and clinical variables, and the proportion of death from prostate cancer vs prior malignancy with\n                      <jats:italic>t<\/jats:italic>\n                      \u2010test and chi\u2010squared analyses. Fine and Gray's regression was used to consider the effect of treatment on prostate cancer death. We then studied a second cohort of 88\u00a0013 men with prostate cancer as a first or second malignancy to describe current diagnostic and treatment patterns.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One in seven men died from prostate cancer in our first cohort. More died from prostate cancer following colorectal cancer (16.8% vs 13.7%), melanoma (13.4% vs 7.56%), and oral cancer (19.1% vs 4.04%), but fewer following bladder cancer, kidney cancer, lung cancer, leukaemia and non\u2010Hodgkin's lymphoma (all\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). Prostate cancer treatment was associated with a nearly 50% lower risk of death when high\u2010grade or high\u2010stage (adjusted hazard ratio 0.55, 95% confidence interval [\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      ] 0.47\u20130.64). Patients who died from prostate cancer had higher grade and stage disease, and received less treatment than patients who died from prior malignancy. The second cohort showed subsequent prostate cancer had more high\u2010risk disease (36.3% vs 22.2%,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) and less prostate cancer treatment (adjusted odds ratio 0.872, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      0.818\u20130.930) than primary prostate cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prostate cancer remains a significant cause of mortality when diagnosed as a subsequent cancer. These results suggest prostate cancer treatment should be seriously considered in patients with prior malignancies, especially those with high\u2010grade or locally advanced prostate cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.13144","type":"journal-article","created":{"date-parts":[[2015,4,4]],"date-time":"2015-04-04T03:38:49Z","timestamp":1428118729000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Risk of prostate cancer mortality in men with a history of prior cancer"],"prefix":"10.1111","volume":"117","author":[{"given":"Kathryn T.","family":"Dinh","sequence":"first","affiliation":[{"name":"Harvard Medical School Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon A.","family":"Mahal","sequence":"additional","affiliation":[{"name":"Harvard Medical School Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Ziehr","sequence":"additional","affiliation":[{"name":"Harvard Medical School Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinayak","family":"Muralidhar","sequence":"additional","affiliation":[{"name":"Harvard Medical School Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu\u2010Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Harvard T.H. Chan School for Public Health Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidya B.","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle D.","family":"Nezolosky","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clair J.","family":"Beard","sequence":"additional","affiliation":[{"name":"Harvard Medical School Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"},{"name":"Department of Radiation Oncology Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Harvard Medical School Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"},{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil E.","family":"Martin","sequence":"additional","affiliation":[{"name":"Harvard Medical School Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"},{"name":"Department of Radiation Oncology Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter F.","family":"Orio","sequence":"additional","affiliation":[{"name":"Harvard Medical School Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"},{"name":"Department of Radiation Oncology Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[{"name":"Harvard Medical School Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"},{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quoc\u2010Dien","family":"Trinh","sequence":"additional","affiliation":[{"name":"Harvard Medical School Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"},{"name":"Division of Urology Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Harvard Medical School Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"},{"name":"Department of Radiation Oncology Dana\u2010Farber Cancer Institute and Brigham and Women's Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,5,23]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_8_2_1","DOI":"10.3322\/caac.21208"},{"doi-asserted-by":"publisher","key":"e_1_2_8_3_1","DOI":"10.1002\/cncr.27672"},{"doi-asserted-by":"publisher","key":"e_1_2_8_4_1","DOI":"10.1016\/j.canep.2012.11.004"},{"doi-asserted-by":"publisher","key":"e_1_2_8_5_1","DOI":"10.1002\/ijc.25480"},{"doi-asserted-by":"publisher","key":"e_1_2_8_6_1","DOI":"10.1016\/j.ejca.2010.03.040"},{"unstructured":"Surveillance Epidemiology and End Results (SEER) Program(www.seer.cancer.gov)SEER*Stat Database: Incidence \u2010 SEER 9 Regs Research Data Nov 2013 Sub (1973\u20132011) <Katrina\/Rita Population Adjustment> \u2010 Linked To County Attributes \u2010 Total U.S. 1969\u20132012 Counties National Cancer Institute DCCPS Surveillance Research Program Surveillance Systems Branch released April 2014 based on the November 2013 submission.","key":"e_1_2_8_7_1"},{"unstructured":"Surveillance Epidemiology and End Results (SEER) Program(www.seer.cancer.gov)SEER*Stat Database: Incidence \u2010 SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases Nov 2013 Sub (1973\u20132011 varying) \u2010 Linked To County Attributes \u2010 Total U.S. 1969\u20132012 Counties National Cancer Institute DCCPS Surveillance Research Program Surveillance Systems Branch released April 2014 (updated 5\/7\/2014) based on the November 2013 submission.","key":"e_1_2_8_8_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_9_1","DOI":"10.1016\/j.juro.2014.06.017"},{"doi-asserted-by":"publisher","key":"e_1_2_8_10_1","DOI":"10.1016\/j.juro.2012.01.070"},{"doi-asserted-by":"publisher","key":"e_1_2_8_11_1","DOI":"10.1016\/j.amjmed.2010.07.031"},{"doi-asserted-by":"publisher","key":"e_1_2_8_12_1","DOI":"10.7150\/ijms.3827"},{"doi-asserted-by":"publisher","key":"e_1_2_8_13_1","DOI":"10.1007\/s11764-013-0278-6"},{"doi-asserted-by":"publisher","key":"e_1_2_8_14_1","DOI":"10.1002\/cam4.116"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.13144","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.13144","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.13144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:25:44Z","timestamp":1761740744000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.13144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,23]]},"references-count":13,"journal-issue":{"issue":"6B","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1111\/bju.13144"],"URL":"https:\/\/doi.org\/10.1111\/bju.13144","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"type":"print","value":"1464-4096"},{"type":"electronic","value":"1464-410X"}],"subject":[],"published":{"date-parts":[[2015,5,23]]},"assertion":[{"value":"2015-05-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}